THERAPY DOSSIER · th-a64b6830b317

Flufenamic acid

Drug · Fenamate NSAID (cyclooxygenase inhibitor; TRP/ion channel modulator); no ChEMBL mechanism record.

Evidence & regulatory context

Mechanism: Fenamate NSAID (cyclooxygenase inhibitor; TRP/ion channel modulator); no ChEMBL mechanism record.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL23588 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Arlef; Meralen; INF-1837
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03238612 ↗PHASE2unknown

Double-blind RCT on Flufenamic Acid for Hospitalised Influenza Infection

Influenza A

Enrolment: 200 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30128046 ↗2018Reported benefit

Flufenamic acid inhibits secondary hemorrhage and BSCB disruption after spinal cord injury.

MouseSpinal cord injuryContusionC57BL/6 and Thy1-GFP-MFemalen = Three groups of n=12 animals per group; histological subana…Intraperitoneal injection12.5 mg/kgFirst dose 1 h after spinal cord injury

Model: Moderate contusion spinal cord injury at T10

Flufenamic acid reduced Trpm4 expression, secondary haemorrhage and capillary fragmentation, promoted angiogenesis, suppressed MMP-2 and MMP-9 at 1 day and attenuated blood-spinal cord barrier disruption at 1 and 3 days. It reduced microglia/macrophage activation, produced smaller lesions and less…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…